A citation-based method for searching scientific literature

Roy Rasalam, John J Atherton, Gary Deed, Michael Molloy-Bland, Neale Cohen, Andrew Sindone. ESC Heart Fail 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
100

Cardiac sympathetic activity in chronic heart failure: cardiac 123I-mIBG scintigraphy to improve patient selection for ICD implantation.
D O Verschure, B L F van Eck-Smit, G A Somsen, R J J Knol, H J Verberne. Neth Heart J 2016
8
100

RobotReviewer: evaluation of a system for automatically assessing bias in clinical trials.
Iain J Marshall, Joël Kuiper, Byron C Wallace. J Am Med Inform Assoc 2016
72
100

Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis.
Husam Ghanim, Sanaa Abuaysheh, Jeanne Hejna, Kelly Green, Manav Batra, Antione Makdissi, Ajay Chaudhuri, Paresh Dandona. J Clin Endocrinol Metab 2020
27
100

Effects of Dapagliflozin on Endothelial Dysfunction in Type 2 Diabetes With Established Ischemic Heart Disease (EDIFIED).
Nur Aisyah Zainordin, Sharifah Faradilla Wan Muhamad Hatta, Fatimah Zaherah Mohamed Shah, Thuhairah Abdul Rahman, Nurhuda Ismail, Zaliha Ismail, Rohana Abdul Ghani. J Endocr Soc 2019
12
100

Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis.
Vinay Garg, Subodh Verma, Kim A Connelly, Andrew T Yan, Aditya Sikand, Ankit Garg, Paul Dorian, Fei Zuo, Lawrence A Leiter, Bernard Zinman,[...]. Metabol Open 2020
7
100


Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri T Kato, Michael G Silverman, Ofri Mosenzon, Thomas A Zelniker, Avivit Cahn, Remo H M Furtado, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
233
100


Reappraising the role of inflammation in heart failure.
Luigi Adamo, Cibele Rocha-Resende, Sumanth D Prabhu, Douglas L Mann. Nat Rev Cardiol 2020
89
100

Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.
Jagdeep S S Singh, Amir Fathi, Keeran Vickneson, Ify Mordi, Mohapradeep Mohan, J Graeme Houston, Ewan R Pearson, Allan D Struthers, Chim C Lang. Cardiovasc Diabetol 2016
39
100

Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes.
Skander Mulder, Hiddo J L Heerspink, Manjula Darshi, Jiwan J Kim, Gozewijn D Laverman, Kumar Sharma, Michelle J Pena. Diabetes Obes Metab 2019
18
100

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Qiang Li, Meg Jardine, Richard Oh,[...]. J Am Soc Nephrol 2019
50
100

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng,[...]. Circulation 2018
132
100

The effect of dapagliflozin treatment on epicardial adipose tissue volume.
Takao Sato, Yoshifusa Aizawa, Sho Yuasa, Shohei Kishi, Koichi Fuse, Satoshi Fujita, Yoshio Ikeda, Hitoshi Kitazawa, Minoru Takahashi, Masahito Sato,[...]. Cardiovasc Diabetol 2018
111
100

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Remo H M Furtado, Marc P Bonaca, Itamar Raz, Thomas A Zelniker, Ofri Mosenzon, Avivit Cahn, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
114
100

Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
Claire C J Dekkers, C David Sjöström, Peter J Greasley, Valerie Cain, David W Boulton, Hiddo J L Heerspink. Diabetes Obes Metab 2019
35
100



Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.
Pooja Dewan, Scott D Solomon, Pardeep S Jhund, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, David L DeMets, Marc S Sabatine,[...]. Eur J Heart Fail 2020
19
100

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
M V Karg, A Bosch, D Kannenkeril, K Striepe, C Ott, M P Schneider, F Boemke-Zelch, P Linz, A M Nagel, J Titze,[...]. Cardiovasc Diabetol 2018
75
100

Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
Subodh Verma, C David Mazer, Mohammed Al-Omran, Silvio E Inzucchi, David Fitchett, Uwe Hehnke, Jyothis T George, Bernard Zinman. Circulation 2018
86
100

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.
Alexander J M Brown, Stephen Gandy, Rory McCrimmon, John Graeme Houston, Allan D Struthers, Chim C Lang. Eur Heart J 2020
38
100

Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
Natalie A Mordi, Ify R Mordi, Jagdeep S Singh, Rory J McCrimmon, Allan D Struthers, Chim C Lang. Circulation 2020
45
100

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
Alice M Jackson, Pooja Dewan, Inder S Anand, Jan Bělohlávek, Olof Bengtsson, Rudolf A de Boer, Michael Böhm, David W Boulton, Vijay K Chopra, David L DeMets,[...]. Circulation 2020
40
100

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Mark C Petrie, Subodh Verma, Kieran F Docherty, Silvio E Inzucchi, Inder Anand, Jan Belohlávek, Michael Böhm, Chern-En Chiang, Vijay K Chopra, Rudolf A de Boer,[...]. JAMA 2020
127
100

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
David Fitchett, Bernard Zinman, Christoph Wanner, John M Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. Eur Heart J 2016
582
100

Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME.
Subodh Verma, Qiuhe Ji, Deepak L Bhatt, C David Mazer, Mohammed Al-Omran, Silvio E Inzucchi, Christoph Wanner, Anne Pernille Ofstad, Isabella Zwiener, Jyothis T George,[...]. Diabetes Obes Metab 2020
11
100


Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial.
Jagdeep S S Singh, Ify R Mordi, Keeran Vickneson, Amir Fathi, Peter T Donnan, Mohapradeep Mohan, Anna Maria J Choy, Stephen Gandy, Jacob George, Faisel Khan,[...]. Diabetes Care 2020
36
100

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
Mikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, Mirta Diez, Mark C Petrie, Subodh Verma, Jose C Nicolau, Béla Merkely, Masafumi Kitakaze, David L DeMets,[...]. Circulation 2020
102
100

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
Alessandro Liberati, Douglas G Altman, Jennifer Tetzlaff, Cynthia Mulrow, Peter C Gøtzsche, John P A Ioannidis, Mike Clarke, P J Devereaux, Jos Kleijnen, David Moher. BMJ 2009
100



Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
Pedro Monteiro, Richard M Bergenstal, Elvira Toural, Silvio E Inzucchi, Bernard Zinman, Stefan Hantel, Sanja Giljanovic Kiš, Stefan Kaspers, Jyothis T George, David Fitchett. Age Ageing 2019
27
100

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, Christopher P Cannon, Bruce Neal, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris,[...]. Circulation 2019
105
100

Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
K Melissa Hallow, Peter J Greasley, Gabriel Helmlinger, Lulu Chu, Hiddo J Heerspink, David W Boulton. Am J Physiol Renal Physiol 2018
25
100

Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13 C magnetic resonance spectroscopy study.
Desiree Abdurrachim, Xing Qi Teo, Chern Chiuh Woo, Wei Xin Chan, Janise Lalic, Carolyn S P Lam, Philip Teck Hock Lee. Diabetes Obes Metab 2019
29
100

Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease.
Adam R Baker, Nancy F da Silva, David W Quinn, Alison L Harte, Domenico Pagano, Robert S Bonser, Sudhesh Kumar, Philip G McTernan. Cardiovasc Diabetol 2006
461
100

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Michael E Nassif, Sheryl L Windsor, Fengming Tang, Yevgeniy Khariton, Mansoor Husain, Silvio E Inzucchi, Darren K McGuire, Bertram Pitt, Benjamin M Scirica, Bethany Austin,[...]. Circulation 2019
137
100

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.
Christian Ott, Agnes Jumar, Kristina Striepe, Stefanie Friedrich, Marina V Karg, Peter Bramlage, Roland E Schmieder. Cardiovasc Diabetol 2017
70
100

Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
Subodh Verma, Abhinav Sharma, Bernard Zinman, Anne Pernille Ofstad, David Fitchett, Martina Brueckmann, Christoph Wanner, Isabella Zwiener, Jyothis T George, Silvio E Inzucchi,[...]. Diabetes Obes Metab 2020
9
100

Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial.
Harpreet S Bajaj, Itamar Raz, Ofri Mosenzon, Sabina A Murphy, Aliza Rozenberg, Ilan Yanuv, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding,[...]. Diabetes Obes Metab 2020
13
100

Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
Jesper Jensen, Massar Omar, Caroline Kistorp, Mikael Kjær Poulsen, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Jens Faber, Emil L Fosbøl,[...]. Am Heart J 2020
21
100

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
David Fitchett, Silvio E Inzucchi, Christopher P Cannon, Darren K McGuire, Benjamin M Scirica, Odd Erik Johansen, Steven Sambevski, Stefan Kaspers, Egon Pfarr, Jyothis T George,[...]. Circulation 2019
92
100



Atrial natriuretic peptide elevation in congestive heart failure in the human.
J C Burnett, P C Kao, D C Hu, D W Heser, D Heublein, J P Granger, T J Opgenorth, G S Reeder. Science 1986
911
100

Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
Kristina Striepe, Agnes Jumar, Christian Ott, Marina V Karg, Markus P Schneider, Dennis Kannenkeril, Roland E Schmieder. Circulation 2017
60
100

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Subodh Verma, C David Mazer, Andrew T Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E Farkouh, David H Fitchett,[...]. Circulation 2019
168
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.